O-0001 International Experts' Consensus for the Definition of Time to Event Endpoints in Clinical Trials (DATECAN Project): Results for Pancreatic Cancer

Authors:

FBFranck Bonnetain
Franck Bonnetain
ADAdelaide Dousseau
Adelaide Dousseau
BBBonsing Bert
Bonsing Bert
GBGlimelius Bengt
Glimelius Bengt
KHKarin Haustermans
Karin Haustermans
TCThierry Conroy
Thierry Conroy
JLJean Luc Van Laethem
Jean Luc Van Laethem
RLRoberto Labianca
Roberto Labianca
TMTeresa Macarulla
Teresa Macarulla
JTJosep Tabernero
Josep Tabernero
MLManfred Lutz
Manfred Lutz
JNJohn P. Neoptolemos
John P. Neoptolemos

Open Access

Publisher website

Google Scholar

1 June 2012

journal article
Published by Elsevier in Annals of Oncology

Vol. 23, iv5-iv18
DOI:10.1093/annonc/mds151

Abstract

Variability in the definition of survival endpoints in oncology trials was identified. Lack of a formal consensus could cause this, which limits inter-trial comparisons. The DATECAN project aimed at obtaining a formal consensus recommendation for defining survival endpoints for randomized clinical trials (RCTs) in the following cancer sites: pancreas, sarcoma/GISTs, breast, colorectal, gastric/œsophagus, head and neck, kidney-bladder. We report results for pancreatic cancer.

Keywords

ORAL PRESENTATIONS